With the recent change in terminology to metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH) and the new cardiometabolic criteria, clinical practice has shifted to incorporate screening of more patients for MASLD/MASH. Employing noninvasive tests (NITs) is essential to identifying patients at high risk for MASH and further disease progression, as well as for selecting patients for the first-ever approved MASH therapy, resmetirom. Cardiometabolic comorbidities are common in these patients, and clinicians must be prepared to manage them, often using glucagon-like peptide-1 receptor agonists (GLP-1 RAs). In this case-based symposium, learners will be divided into teams and will compete to correctly answer clinical decision questions within each case. Each team will be led by our expert faculty, Drs. Vlad Ratziu and Rohit Loomba, with the didactic content presented as an explanation of the correct answer to each question. Topics covered will include nuances of diagnosis and staging using NITs, selecting candidates for resmetirom, and optimal management strategies, such as GLP-1 RAs, for the management of common cardiometabolic comorbidities. Join us for this fun, exciting, and competitive program and see if you have what it takes to win! | 
